- Home
- SANW vs INAB Comparison
SANW vs INAB Comparison
Compare SANW & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANW
- INAB
- Stock Information
- Founded
- SANW 1980
- INAB 2016
- Country
- SANW United States
- INAB United States
- Employees
- SANW N/A
- INAB N/A
- Industry
- SANW Farming/Seeds/Milling
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SANW Consumer Staples
- INAB Health Care
- Exchange
- SANW Nasdaq
- INAB Nasdaq
- Market Cap
- SANW 18.8M
- INAB 18.8M
- IPO Year
- SANW 2010
- INAB 2021
- Fundamental
- Price
- SANW $7.12
- INAB $0.17
- Analyst Decision
- SANW Strong Buy
- INAB Strong Buy
- Analyst Count
- SANW 1
- INAB 2
- Target Price
- SANW $35.00
- INAB $3.60
- AVG Volume (30 Days)
- SANW 6.2K
- INAB 1.1M
- Earning Date
- SANW 05-13-2025
- INAB 03-13-2025
- Dividend Yield
- SANW N/A
- INAB N/A
- EPS Growth
- SANW N/A
- INAB N/A
- EPS
- SANW N/A
- INAB N/A
- Revenue
- SANW $54,809,365.00
- INAB N/A
- Revenue This Year
- SANW N/A
- INAB N/A
- Revenue Next Year
- SANW $9.92
- INAB N/A
- P/E Ratio
- SANW N/A
- INAB N/A
- Revenue Growth
- SANW N/A
- INAB N/A
- 52 Week Low
- SANW $2.10
- INAB $0.16
- 52 Week High
- SANW $11.60
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- SANW 44.22
- INAB 28.22
- Support Level
- SANW $6.73
- INAB $0.16
- Resistance Level
- SANW $8.22
- INAB $0.25
- Average True Range (ATR)
- SANW 0.67
- INAB 0.02
- MACD
- SANW -0.04
- INAB -0.01
- Stochastic Oscillator
- SANW 37.50
- INAB 13.08
About SANW S&W Seed Company (NV)
S&W Seed Co is a multi-crop, middle-market agricultural company. It is engaged in the breeding, production, and sale of alfalfa seed and sorghum seed. It also has a growing commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers globally. Its geographical segments include the United States, Australia, Saudi Arabia, Mexico, South Africa, and other countries. Maximum of revenue is earned from USA following Australia second and Mexico third.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.